

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jonassen et al.

Application No.: To be assigned

Group Art Unit: To be assigned

Filed: January 30, 2001

Examiner: To be assigned

For: Protracted Polypeptides



INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. Copies of references were filed with USSN 09/068,822 filed May 14, 1998, the benefit of which is claimed under 35 USC 120.

The references are as follows:

1. EP 0 511 600
2. USP 5,359,030
3. PCT WO 93/15750


4. PCT WO 93/21320
5. Abstract, File 73, Dialog Accession No. 8421240
6. Abstract, File 434, Dialog Accession No. 12616071
7. Abstract, File 434, Dialog Accession No. 13565514
8. Chemical Abstracts, Vol. 123, No. 10, The Abstract No. 122862m
9. Chemical Abstracts, Vol. 118, No. 16, The Abstract No. 154346j

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed on filing date of application. Therefore, no fee is due.

Respectfully submitted,

Date: January 30, 2001

  
Valeta A. Gregg, Reg. No. 35,127  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123